These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 36274133)

  • 1. Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards.
    Rieke DT; de Bortoli T; Horak P; Lamping M; Benary M; Jelas I; Rüter G; Berger J; Zettwitz M; Kagelmann N; Kind A; Fabian F; Beule D; Glimm H; Brors B; Stenzinger A; Fröhling S; Keilholz U
    BMC Med; 2022 Oct; 20(1):367. PubMed ID: 36274133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Added value of whole-exome and RNA sequencing in advanced and refractory cancer patients with no molecular-based treatment recommendation based on a 90-gene panel.
    Dufresne A; Attignon V; Ferrari A; Tonon L; Boyault S; Tabone-Eglinger S; Cassier P; Trédan O; Corradini N; Vinceneux A; Swalduz A; Viari A; Chabaud S; Pérol D; Blay JY; Saintigny P
    Cancer Med; 2024 Apr; 13(7):e7115. PubMed ID: 38553950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.
    Oberg JA; Glade Bender JL; Sulis ML; Pendrick D; Sireci AN; Hsiao SJ; Turk AT; Dela Cruz FS; Hibshoosh H; Remotti H; Zylber RJ; Pang J; Diolaiti D; Koval C; Andrews SJ; Garvin JH; Yamashiro DJ; Chung WK; Emerson SG; Nagy PL; Mansukhani MM; Kung AL
    Genome Med; 2016 Dec; 8(1):133. PubMed ID: 28007021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying the Value of the Molecular Tumor Board: Discordance Recommendation Rate and Drug Cost Avoidance.
    Walters MK; Ackerman AT; Weese JL; Ruggeri A; Mullane MP; Hunt A; Wilson A; Ramczyk BL; Thompson MA
    JCO Precis Oncol; 2022 Oct; 6():e2200132. PubMed ID: 36265115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22-09.
    Kim SY; Kim JH; Kim TY; Park SR; Yoon S; Lee S; Lee SH; Kim TM; Han SW; Kim HR; Yun H; Lee S; Kim J; Choi YL; Choi KS; Chae H; Ryu H; Lee GW; Zang DY; Ahn JB
    BMC Cancer; 2024 May; 24(1):574. PubMed ID: 38724991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors.
    Vodicska B; Déri J; Tihanyi D; Várkondi E; Kispéter E; Dóczi R; Lakatos D; Dirner A; Vidermann M; Filotás P; Szalkai-Dénes R; Szegedi I; Bartyik K; Gábor KM; Simon R; Hauser P; Péter G; Kiss C; Garami M; Peták I
    World J Pediatr; 2023 Oct; 19(10):992-1008. PubMed ID: 36914906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Support of a molecular tumour board by an evidence-based decision management system for precision oncology.
    Lamping M; Benary M; Leyvraz S; Messerschmidt C; Blanc E; Kessler T; Schütte M; Lenze D; Jöhrens K; Burock S; Klinghammer K; Ochsenreither S; Sers C; Schäfer R; Tinhofer I; Beule D; Klauschen F; Yaspo ML; Keilholz U; Rieke DT
    Eur J Cancer; 2020 Mar; 127():41-51. PubMed ID: 31982633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
    Giacomini P; Valenti F; Allegretti M; Pallocca M; De Nicola F; Ciuffreda L; Fanciulli M; Scalera S; Buglioni S; Melucci E; Casini B; Carosi M; Pescarmona E; Giordani E; Sperati F; Jannitti N; Betti M; Maugeri-Saccà M; Cecere FL; Villani V; Pace A; Appetecchia M; Vici P; Savarese A; Krasniqi E; Ferraresi V; Russillo M; Fabi A; Landi L; Minuti G; Cappuzzo F; Zeuli M; Ciliberto G
    J Transl Med; 2023 Oct; 21(1):725. PubMed ID: 37845764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
    Tafe LJ; Gorlov IP; de Abreu FB; Lefferts JA; Liu X; Pettus JR; Marotti JD; Bloch KJ; Memoli VA; Suriawinata AA; Dragnev KH; Fadul CE; Schwartz GN; Morgan CR; Holderness BM; Peterson JD; Tsongalis GJ; Miller TW; Chamberlin MD
    Oncologist; 2015 Sep; 20(9):1011-8. PubMed ID: 26205736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and clinical application of an integrative genomic approach to personalized cancer therapy.
    Uzilov AV; Ding W; Fink MY; Antipin Y; Brohl AS; Davis C; Lau CY; Pandya C; Shah H; Kasai Y; Powell J; Micchelli M; Castellanos R; Zhang Z; Linderman M; Kinoshita Y; Zweig M; Raustad K; Cheung K; Castillo D; Wooten M; Bourzgui I; Newman LC; Deikus G; Mathew B; Zhu J; Glicksberg BS; Moe AS; Liao J; Edelmann L; Dudley JT; Maki RG; Kasarskis A; Holcombe RF; Mahajan M; Hao K; Reva B; Longtine J; Starcevic D; Sebra R; Donovan MJ; Li S; Schadt EE; Chen R
    Genome Med; 2016 Jun; 8(1):62. PubMed ID: 27245685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
    Koopman B; Groen HJM; Ligtenberg MJL; Grünberg K; Monkhorst K; de Langen AJ; Boelens MC; Paats MS; von der Thüsen JH; Dinjens WNM; Solleveld N; van Wezel T; Gelderblom H; Hendriks LE; Speel EM; Theunissen TE; Kroeze LI; Mehra N; Piet B; van der Wekken AJ; Ter Elst A; Timens W; Willems SM; Meijers RWJ; de Leng WWJ; van Lindert ASR; Radonic T; Hashemi SMS; Heideman DAM; Schuuring E; van Kempen LC
    Oncologist; 2021 Aug; 26(8):e1347-e1358. PubMed ID: 33111480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine.
    Van Allen EM; Robinson D; Morrissey C; Pritchard C; Imamovic A; Carter S; Rosenberg M; McKenna A; Wu YM; Cao X; Chinnaiyan A; Garraway L; Nelson PS
    Oncotarget; 2016 Aug; 7(33):52888-52899. PubMed ID: 27167109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of a molecular tumor board at a regional level to improve access to targeted therapy.
    Bourien H; Lespagnol A; Campillo-Gimenez B; Felten-Vinot I; Metges JP; Corre R; Lesimple T; le Marechal C; Boussemart L; Kammerer-Jacquet SF; le Gall E; Denoual F; de Tayrac M; Galibert MD; Mosser J; Edeline J
    Int J Clin Oncol; 2020 Jul; 25(7):1234-1241. PubMed ID: 32215806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group.
    Yoon S; Kim M; Hong YS; Kim HS; Kim ST; Kim J; Yun H; Yoo C; Ahn HK; Kim HS; Lee IH; Kim IH; Park I; Jeong JH; Cheon J; Kim JW; Yun J; Lim SM; Cha Y; Jang SJ; Zang DY; Kim TW; Kang JH; Kim JH
    Cancer Res Treat; 2022 Jan; 54(1):1-9. PubMed ID: 34902959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology.
    Jobanputra V; Wrzeszczynski KO; Buttner R; Caldas C; Cuppen E; Grimmond S; Haferlach T; Mullighan C; Schuh A; Elemento O
    Semin Cancer Biol; 2022 Sep; 84():23-31. PubMed ID: 34256129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized oncology through integrative high-throughput sequencing: a pilot study.
    Roychowdhury S; Iyer MK; Robinson DR; Lonigro RJ; Wu YM; Cao X; Kalyana-Sundaram S; Sam L; Balbin OA; Quist MJ; Barrette T; Everett J; Siddiqui J; Kunju LP; Navone N; Araujo JC; Troncoso P; Logothetis CJ; Innis JW; Smith DC; Lao CD; Kim SY; Roberts JS; Gruber SB; Pienta KJ; Talpaz M; Chinnaiyan AM
    Sci Transl Med; 2011 Nov; 3(111):111ra121. PubMed ID: 22133722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes of Molecular Tumor Boards: A Systematic Review.
    Larson KL; Huang B; Weiss HL; Hull P; Westgate PM; Miller RW; Arnold SM; Kolesar JM
    JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34632252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordance in Recommendation Between Next-Generation Sequencing Test Reports and Molecular Tumor Boards in India.
    Mathew A; Davis S; Boby JM; R I A; Suryavanshi M; Dawood SS; Panda PK; Nag SM; Das A; Rohatgi N; Popat S; Shah RNH; Thampy C; Parikh AR; Yadav S; Mehta P; Singh R; Mukherji D; Shilpakar R; Mullapally SK; Sirohi B
    JCO Glob Oncol; 2024 Mar; 10():e2300330. PubMed ID: 38484196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program 'iTHER'.
    Langenberg KPS; Meister MT; Bakhuizen JJ; Boer JM; van Eijkelenburg NKA; Hulleman E; Ilan U; Looze EJ; Dierselhuis MP; van der Lugt J; Breunis W; Schild LG; Ober K; van Hooff SR; Scheijde-Vermeulen MA; Hiemcke-Jiwa LS; Flucke UE; Kranendonk MEG; Wesseling P; Sonneveld E; Punt S; Boltjes A; van Dijk F; Verwiel ETP; Volckmann R; Hehir-Kwa JY; Kester LA; Koudijs MMJ; Waanders E; Holstege FCP; Vormoor HJ; Hoving EW; van Noesel MM; Pieters R; Kool M; Stumpf M; Blattner-Johnson M; Balasubramanian GP; Van Tilburg CM; Jones BC; Jones DTW; Witt O; Pfister SM; Jongmans MCJ; Kuiper RP; de Krijger RR; Wijnen MHW; den Boer ML; Zwaan CM; Kemmeren P; Koster J; Tops BBJ; Goemans BF; Molenaar JJ
    Eur J Cancer; 2022 Nov; 175():311-325. PubMed ID: 36182817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.